Serum 25-hydroxyvitamin D level in psoriasis patients: a case-control study

Surinder Gupta, Preeti Garg, Nakul Gupta


Background: Sufficient level of vitamin D in blood is required for proper regulation of cell differentiation and proliferation. Unchecked proliferation of cells leads to various disease states. Vitamin D also has immunomodulatory effects in the body. Psoriasis is a chronic inflammatory and hyperproliferative disease with vitamin D having an impact on it. This case – control study was done to judge the levels of vitamin D in patients of psoriasis compared to age and sex matched controls.

Methods: A case control study was conducted including 50 patients (35 females and 15 males) of chronic plaque psoriasis from dermatology outpatient department of Maharaja Agrasen Medical College (MAMC), Agroha, Haryana, representing patients from north India and 50 healthy controls. Both urban and rural background patients were included.

Results: The mean serum 25-hydroxyvitamin D (25-OHD) level in psoriasis patients was 22.865±11.386 ng/ml, whereas in controls it was 35.116±11.048 ng/ml (p<0.001). Serum level of 25-OHD in psoriatic patients was deficient (<20 ng/ml) in 26 (52%), insufficient (20-30 ng/ml) in 8 (16%) psoriatic patients.

Conclusions: High prevalence of low vitamin D level was found in this study. We infer that vitamin D does play a role in the pathogenesis, precipitation, exacerbation, or treatment resistance of psoriasis.



Psoriasis, Vitamin D level, Pathogenesis

Full Text:



Christopher E, Kruger G. Psoriasis. In: Fitzpatrick TB, Eisen AZ, Wollf K, editors. Dermatology in general medicine. 3rd ed. New York: Mc Graw-Hill; 2008: 169.

Napolitano M, Caso F, Scarpa R, Megna M, Patrì A, Balato N, et al. Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol. 2016;35(8):1893–901.

Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26(Suppl 2):3–11.

Napolitano M, Megna M, Monfrecola G. Insulin resistance and skin diseases. Sci World J. 2015;2015:479354.

Lønnberg AS, Skov L. Co-morbidity in psoriasis: mechanisms and implications for treatment. Expert Rev Clin Immunol. 2016;28:1–8.

Dommasch ED, Troxel AB, Gelfand JM. Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses. J Am Acad Dermatol 2013;68:863-5.

Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin Dermatol. 2014;32:343-50.

Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19:225-30.

Shaharyar S, Warraich H, McEvoy JW, Oni E, Ali SS, Karim A, et al. Subclinical cardiovascular disease in plaque psoriasis: association or causal link? Atherosclerosis. 2014;232:72-8.

Asokan N, Prathap P, Rejani P. Severity of psoriasis among adult males is associated with smoking, not with alcohol use. Indian J Dermatol. 2014;59:237-40.

Lakshmi S, Nath AK, Udayashankar C. Metabolic syndrome in patients with psoriasis: A comparative study. Indian Dermatol Online J. 2014;5:132-7.

Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol. 2014;7:119-32.

Soleymani T, Hung T, Soung J. The role of vitamin D in psoriasis: a review. Int J Dermatol. 2015;54(4):383–92.

Wadhwa B, Relhan V, Goel K,KochharAM, Garg VK.VitaminD and skin diseases: a review. Indian J Dermatol Venereol Leprol. 2015;81(4):344–55.

Matsumoto K, Hashimoto K, Nishida Y, Hashiro M, Yoshikawa K. Growth-inhibitory effects of 1,25-dihydroxyvitamin D3 on normal human keratinocytes cultured in serum-free medium. Biochem Biophys Res Commun. 1990;166(2):916–23.

Reichrath J. Vitamin D and the skin: An ancient friend, revisited. Exp Dermatol. 2007;16(7):618–25.

Gniadecki R. Stimulation versus inhibition of keratinocyte growth by 1,25 dihydroxyvitamin D3: dependence on cell culture conditions. J Invest Dermatol. 1996;106(3):510–6.

Hegyi Z, Zwicker S, Bureik D, Peric M, Koglin S, Batycka-Baran A, et al. Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 "alarmins" psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis. J Invest Dermatol. 2012;132(5):1416–24.

Tu CL, Oda Y, Komuves L, Bikle DD. The role of the calcium sensing receptor in epidermal differentiation. Cell Calcium. 2004;35:265–73.

Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–55.

Harari M, Shani J, Hristakieva E, Stanimirovic A, Seidl W, Burdo A. Clinical evaluation of a more rapid and sensitive psoriasis assessment severity score (PASS), and its comparison with the classic method of psoriasis area and severity index (PASI), before and after climatotherapy at the Dead-Sea. Int J Dermatol. 2000;39(12):913–8.

Heilborn JD, Weber G, Gronberg A, Dieterich C, Stahle M. Topical treatment with the vitamin D analogue calcipotriol enhances the upregulation of the antimicrobial protein hCAP18/ LL-37 during wounding in human skin in vivo. Exp Dermatol. 2010;19:332–8.

Mostafa WZ, Hegazy RA. Vitamin D and the skin: focus on a complex relationship: a review. J Adv Res. 2014;6:793-804.

Lesiak A, Narbutt J, Pawlaczyk M, Sysa-Jedrzejowska A, Krzyścin J. Vitamin D serum level changes in psoriatic patients treated with narrowband ultraviolet B phototherapy are related to the season of the irradiation. Photodermatol Photoimmunol Photomed. 2011;27:304-10.

Cicarma E, Mork C, Porojnicu AC, Juzeniene A, Tam TT, Dahlback A, et al. Influence of narrowband UVB phototherapy on vitamin D and folate status. Exp Dermatol. 2010;19:67-72.

Ryan C, Moran B, McKenna MJ, Murray BF, Brady J, Collins P, et al. The effect of narrowband UV-B treatment for psoriasis on vitamin D status during wintertime in Ireland. Arch Dermatol. 2010;146:836-42.

Ala-houhala MJ, Karppinen TT, Vahavihu K, Kautiainen H, Dombrowski Y, Snellman E, et al. Narrowband ultraviolet B treatment boosts serum 25-hydroxyvitamin D in patients with psoriasis on oral vitamin D supplementation. Acta Derm Venereol. 2014;94:146-51.

Osmancevic A, Landin-Wilhelmsen K, Larko O, Krogstad AL. Vitamin D status in psoriasis patients during different treatments with phototherapy. J Photochem Photobiol B. 2010;101:117-23.

Morimoto S, Kumahara Y. A patient with psoriasis cured by 1 alpha-hydroxyvitamin D3. Med J Osaka Univ. 1985;35(3-4):51-4.

Orgaz-Molina J, Buendia-Eisman A, Arrabal-Polo MA, Ruiz JC, Arias-Santiago S. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: a case-control study. J. Am. Acad. Dermatol. 2012;67:931–8.

Gisondi P, Rossini M, Cesare A Di, Idolazzi L, Farina S, Beltrami G, et al. Vitamin D status in patients with chronic plaque psoriasis. Br J. Dermatol. 2012;166:505–10.

Ricceri F, Pescitelli L, Tripo L, Prignano F. Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis. J. Am. Acad. Dermatol. 2013;68:511–12.

Srirama L. Serum concentration of 25-hydroxy vitamin D in psoriatic patients in a tertiary care hospital - A case control study. IAIM. 2016;3(1):97-104.

Pavlov SI, Ivanova II, Gerova D. Vitamin D status in patients with psoriasis. Scr Sci Med. 2016;8:50-4.

Werner de Castro GR, Neves FS, Pereira IA, Fialho SC, Ribeiro G, Zimmermann AF. Resolution of adalimumab-induced psoriasis after vitamin D deficiency treatment. Rheumatol Int. doi: 10.1007/s00296-011-1799-9.

Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996;134:1070-8.

Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris: a randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol. 1992;27:983-8.